Plural Carboxamide Groups Or Plural C=o Groups Bonded Directly To The Same Nitrogen Patents (Class 514/616)
-
Patent number: 8729293Abstract: The invention relates to Fatty Acid Acetylated Salicylate Derivatives; compositions comprising an effective amount of a Fatty Acid Acetylated Salicylate Derivative; and methods for treating or preventing an inflammatory disorder comprising the administration of an effective amount of a Fatty Acid Acetylated Salicylate Derivative.Type: GrantFiled: March 22, 2012Date of Patent: May 20, 2014Assignee: Catabasis Pharmaceuticals, Inc.Inventors: Jill C. Milne, Michael R. Jirousek, Jean E. Bemis, Jesse J. Smith
-
Patent number: 8729130Abstract: Novel solid forms of tacedinaline (4-(acetylamino)-N-(2-aminophenyl)benzamide), including crystalline tacedinaline Forms A, B, and D, a novel crystalline tacedinaline TFA salt, and amorphous tacedinaline, are disclosed. Pharmaceutical compositions comprising crystalline tacedinaline Forms A, B, and D, the novel crystalline tacedinaline TFA salt, and/or amorphous tacedinaline, and methods of treating various conditions by administering those novel solid forms, are also disclosed.Type: GrantFiled: September 15, 2012Date of Patent: May 20, 2014Assignee: The Broad Institute, Inc.Inventors: Edward Holson, Florence F. Wagner, G. Patrick Stahly
-
Publication number: 20140135334Abstract: A biocidal composition comprising 2,2-dibromomalonamide and an aldehyde-based biocidal compound, and its use for the control of microorganisms in aqueous and water-containing systems.Type: ApplicationFiled: November 15, 2013Publication date: May 15, 2014Inventors: Bei Yin, Freddie L. Singleton
-
Publication number: 20140135401Abstract: The present invention provides arachidonic acid (AA) analogs and compositions containing those analogs as active agents for use in analgesic treatments. Various methods of manufacturing the inventive compounds are provided and pharmaceutical formulations, including injectable and oral dosages, are described. Certain analogs are additionally useful as antipyretic compositions and in related fever reducing treatments.Type: ApplicationFiled: January 17, 2014Publication date: May 15, 2014Applicant: CYTOMETIX, INC.Inventors: Lane Brostrom, John R. Falck
-
Publication number: 20140128378Abstract: The present invention is directed to the use of a class of peptide Compounds for prevention, alleviation or/and treatment of refractory Status epilepticus.Type: ApplicationFiled: January 14, 2014Publication date: May 8, 2014Applicant: UCB Pharma GmbHInventor: Thomas STÖHR
-
Publication number: 20140128377Abstract: The present invention is directed to the use of a class of peptide Compounds for prevention, alleviation or/and treatment of refractory Status epilepticus.Type: ApplicationFiled: January 14, 2014Publication date: May 8, 2014Applicant: UCB Pharma GmbHInventor: Thomas STÖHR
-
Publication number: 20140128463Abstract: Disclosed are amide compounds, preparation method and uses thereof, specifically, the compounds represented by formula I or pharmaceutically acceptable salts, wherein R1, R2, R3, R4, R5, Q, X and n are defined as in the description. Also disclosed are a method for preparing the compounds of formula I, a composition containing the compounds, and the uses of the same in the preparation of medicaments for regulating blood lipid and/or preventing gallstone. The compounds of formula I disclosed in the present invention have stability in vitro, good solubility in the pharmaceutical organic solvents and favorable bioavailability in animals.Type: ApplicationFiled: June 25, 2012Publication date: May 8, 2014Applicants: China State Institute of Pharmaceutic Industry, Shanghai Institute of Pharmaceutical IndustryInventors: Zhenpeng Yu, Gouping Wang, Zhen Zhang, Minyu Liu, Xiaoling Huang, Ying Liu, Lin Xiao, Li Cai, Xuejun Wu, Yifang Deng, Mianli Pan, Renhai Chen, Shenrong Tang, Quanhai Liu
-
Patent number: 8716345Abstract: The present invention relates to inhibitors of the 11-beta-hydroxysteroid dehydrogenase Type 1 enzyme and their use in treatment of non-insulin dependent type 2 diabetes, insulin resistance, obesity, lipid disorders, metabolic syndrome, central nervous system disorders, and diseases and conditions that are related to excessive glucocorticoids.Type: GrantFiled: June 22, 2012Date of Patent: May 6, 2014Assignee: AbbVie Inc.Inventors: R. Scott Bitner, Kaitlin E. Browman, Michael E. Brune, Steven Fung, Peer B. Jacobson, Lynne E. Rueter, Marina I. Strakhova, Jiahong Wang, Jyoti R. Patel, Qi Shuai, James T. Link, Jeffrey J. Rohde, Jurgen Dinges, Bryan K. Sorensen, Martin Winn, Hong Yong, Vince S. Yeh
-
Patent number: 8716284Abstract: The present invention provides adamantyl-diamide derivatives of formula (I): wherein R1 and R2 are as defined herein, or a pharmaceutically acceptable salt thereof; and pharmaceutical compositions and methods using the same.Type: GrantFiled: February 1, 2013Date of Patent: May 6, 2014Assignee: H. Lundbeck A/SInventors: Hermogenes N. Jimenez, Guiying Li, Dario Doller, Michel Grenon, Andrew D. White, Gil Ma, Maojun Guo
-
Patent number: 8716343Abstract: A class of topomimetic calixarene-based peptide mimetics is described. Calixarene-based peptide mimetics have various biological activities such as, for example, bactericidal activity, antiangiogenic activity, and/or antitumor activity. Methods of use and methods of designing calixarene-based peptide mimetics are described.Type: GrantFiled: April 24, 2012Date of Patent: May 6, 2014Assignee: Regents of the University of MinnesotaInventors: Kevin H. Mayo, Thomas R. Hoye, Xuemei Chen
-
Patent number: 8716530Abstract: The present invention discloses methods of use of facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers, including, but not limited to, pharmaceutical uses of the polymers and oligomers as antimicrobial agents and as antidotes for hemorrhagic complications associated with heparin therapy. The present invention also discloses novel facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers, compositions of the novel polymers and oligomers, including pharmaceutical compositions, and methods of designing and synthesizing the facially amphiphilic polyaryl and polyarylalkynyl polymers and oligomers.Type: GrantFiled: February 3, 2012Date of Patent: May 6, 2014Assignee: The Trustess of the University of PennsylvaniaInventors: William F. DeGrado, Dahui Liu, Gregory N. Tew, Michael L. Klein
-
Publication number: 20140121279Abstract: The present invention relates to dipeptide enkephalin analogues of Formula (I) and their tautomers, ionic forms and pharmaceutically acceptable salts, and their use in medicine, in particular as opioid agonists.Type: ApplicationFiled: June 29, 2012Publication date: May 1, 2014Applicant: Pfizer LimitedInventor: Dafydd Rhys Owen
-
Publication number: 20140121278Abstract: Disclosed herein are compositions comprising a galectin-1-targeting compound in a therapeutically effective composition for treating cancer. In an aspect, a galectin-1-targeting compound is OTX-008. Also disclosed herein are methods of making and using such compositions.Type: ApplicationFiled: November 1, 2012Publication date: May 1, 2014Applicant: Regents of the University of MinnesotaInventor: KEVIN H. MAYO
-
Patent number: 8709513Abstract: Disclosed are suspension concentrate compositions comprising by weight based on the total weight of the composition, (a) from about 0.1 to about 50% of one or more carboxamide arthropodicides that are solid at room temperature; ( b) from 0 to about 50% of one or more biologically active agents other than the carboxamide arthropodicides; (c) from about 20 to about 70% of water; (d) from about 10 to about 70% of one or more water-immiscible liquid compounds; and (e) from about 1 to about 55% of a surfactant component having a dispersing property. This invention also relates to a method for controlling an arthropod pest comprising diluting said suspension concentrate composition with water, optionally adding an adjuvant to form a diluted composition, and contacting the arthropod pest or its environment with an effective amount of said diluted composition.Type: GrantFiled: November 30, 2007Date of Patent: April 29, 2014Assignee: E I du Pont de Nemours and CompanyInventors: Oliver Walter Gutsche, Isaac Billy Annan, Hector Eduardo Portillo
-
Patent number: 8704001Abstract: This invention relates to novel 2-amino-3-hydroxypropanoic acid derivatives and pharmaceutically acceptable salts thereof. This invention also provides compositions comprising a compound of this invention and the use of such compositions in methods of treating diseases and conditions that are beneficially treated by administering an NMDA glycine-site antagonist.Type: GrantFiled: September 15, 2009Date of Patent: April 22, 2014Assignee: Concert Pharmaceuticals, Inc.Inventor: Craig E. Masse
-
Publication number: 20140107134Abstract: The invention relates to compounds of formula (I): or a pharmaceutically acceptable salt, solvate, clathrate, or prodrug thereof wherein X, Y, A, Z, L and n are defined herein. These compounds are useful as immunosuppressive agents and for treating and preventing inflammatory conditions and immune disorders.Type: ApplicationFiled: September 27, 2013Publication date: April 17, 2014Applicant: Synta Pharmaceuticals Corp.Inventors: Yu Xie, Mats Holmqvist, Jerome Mahiou, Mitsunori Ono, Lijun Sun, Shoujun Chen, Shijie Zhang, Jun Jiang, Dinesh Chimmanamada, Chih-Yi Yu
-
Patent number: 8697729Abstract: Disclosed are methods and compositions for modulating the function of transcription factors, especially transcription factors that recruit epigenetic regulators (histone modifying enzymes) to specific DNA promoters. The targeted transcription factors include but are not limited to the myocyte enhancing factor (MEF2), the forkhead/winged helix transcription factor FOXP3 and the transcription factor GATA3. Also disclosed are small molecule modulators of MEF2 and its associated factors that include but not limited to histone deacetylases (HDACs), p300/CBP and Cabin1 and the therapeutic applications thereof.Type: GrantFiled: November 5, 2009Date of Patent: April 15, 2014Assignee: University of Southern CaliforniaInventors: Lin Chen, Nimanthi Jayathilaka, Aidong Han, Nicos Petasis
-
Patent number: 8691875Abstract: Novel solid forms of tacedinaline (4-(acetylamino)-N-(2-aminophenyl)benzamide), including crystalline tacedinaline Forms A, B, and D, a novel crystalline tacedinaline TFA salt, and amorphous tacedinaline, are disclosed. Pharmaceutical compositions comprising crystalline tacedinaline Forms A, B, and D, the novel crystalline tacedinaline TFA salt, and/or amorphous tacedinaline, and methods of treating various conditions by administering those novel solid forms, are also disclosed.Type: GrantFiled: September 15, 2012Date of Patent: April 8, 2014Assignee: Broad Institute, Inc.Inventors: Edward Holson, Florence F. Wagner, G. Patrick Stahly
-
Publication number: 20140094457Abstract: The present invention relates to pharmaceutical compositions comprising a compound and a pharmaceutically acceptable carrier. The present invention is also directed to a method of treating a genetic disease caused by premature termination codons, or other conditions that render messenger ribonucleic acid (mRNA) susceptible to nonsense mediated RNA decay, in a subject. Also disclosed is a method of inhibiting nonsense mediated RNA decay and/or induction of autophagy. The present invention also relates to a method of identifying inhibitors of nonsense mediated RNA decay and/or inducing autophagy. The present invention further relates to a method of inhibiting nonsense mediated RNA decay and/or induction of autophagy in a subject.Type: ApplicationFiled: October 2, 2013Publication date: April 3, 2014Applicant: NEW YORK UNIVERSITYInventors: Lawrence B. Gardner, Timothy J. Cardozo, Leenus Martin
-
Publication number: 20140094521Abstract: The objective of the present invention is to provide a new compound which is effective in treating blood cancer, particularly multiple myeloma, and which is also effective in suppressing an SP cell, i.e. Side Population Cell, which is a cause of recurrence of cancer. The compound according to the present invention is a novel compound which has the specific benzylamine structure.Type: ApplicationFiled: May 23, 2012Publication date: April 3, 2014Applicant: THE UNIVERSITY OF TOKUSHIMAInventors: Daisuke Tsuji, Kohji Itoh, Akira Otaka, Akira Shigenaga, Masahiro Abe, Masahiro Hiasa
-
Publication number: 20140093513Abstract: The invention relates to new methods of modulating cholesterol by inhibiting proprotein convertase subtilisin/kexin type 9 (PCSK9) with fatty acid derivatives; and new methods for treating or preventing a metabolic disease comprising the administration of an effective amount of a fatty acid derivative. The present invention is also directed to fatty acid bioative derivatives and their use in the treatment of metabolic diseases.Type: ApplicationFiled: May 24, 2013Publication date: April 3, 2014Applicant: Catabasis Pharmaceuticals, Inc.Inventors: Jill C. Milne, Michael R. Jirousek, Chi B. Vu
-
Patent number: 8686045Abstract: Methods and compounds for treating neurological and other disorders are provided. Included is the administering to a subject in need thereof an effective amount of a compound having binding and/or modulation specificity for a TrkB receptor molecule.Type: GrantFiled: June 8, 2006Date of Patent: April 1, 2014Assignees: The University of North Carolina at Chapel Hill, The Regents of the University of California, The United States of America as represented by the Department of Veterans AffairsInventors: Frank M. Longo, Stephen M. Massa
-
Patent number: 8686044Abstract: An amide derivative represented by the following Formula (1) is provided as an amide derivative showing a significantly excellent effect for a pest control action. In the following Formula (1), A represents a carbon atom, a nitrogen atom, or the like, and K represents a non-metal atomic group necessary for forming a cyclic linking group derived from benzene or a heterocyclie. X represents a halogen atom or the like; n represents an integer of from 0 to 4. R1 and R2 represent hydrogen atoms, alkyl groups, or the like. T represents —C(=G1)-Q1 or —C(=G1)-G2Q2, and G1 to G3 each represent oxygen atoms or the like. Q1 and Q2 each represent a hydrogen atom, an alkyl group, an aryl group, or the like. Y1 and Y5 each represent a halogen atom or the like, Y2 and Y4 each represent a hydrogen atom or the like, and Y3 represents a C2-C5 haloalkyl group.Type: GrantFiled: January 28, 2011Date of Patent: April 1, 2014Assignee: Mitsui Chemicals Agro, Inc.Inventors: Yumi Kobayashi, Hidenori Daido, Hiroyuki Katsuta, Michikazu Nomura, Hidetaka Tsukada, Atsushi Hirabayashi, Yusuke Takahashi, Yoji Aoki, Atsuko Kawahara, Yasuaki Fukazawa, Mai Hirose
-
Patent number: 8680151Abstract: Compositions and methods of treating or preventing disease or injury to a human patient or biological material undergoing ischemic or hypoxic conditions.Type: GrantFiled: February 11, 2011Date of Patent: March 25, 2014Assignee: Fred Hutchinson Cancer Research CenterInventors: Fuqiang Ruan, Edward A. Wintner, Thomas L. Deckwerth
-
Patent number: 8680152Abstract: The present invention is directed to methods of using compounds that are inhibitors of cysteine proteases, in particular, of both cathepsins S and K and optionally further cathepsins B and/or L in treating bone cancer. The present invention is directed to pharmaceutical compositions comprising these compounds for treating bone cancer and bone cancer pain, especially the pain associated with metastasis. A single compound can be used to ameliorate the pain, the injury to bone, while also reducing tumor growth, the risk of metastasis and/or invasiveness of the cancer.Type: GrantFiled: May 2, 2012Date of Patent: March 25, 2014Assignee: Virobay, Inc.Inventor: Robert Booth
-
Publication number: 20140080905Abstract: This invention relates to the treatment of androgen receptor-positive breast cancer in a subject, for example a female subject.Type: ApplicationFiled: July 29, 2013Publication date: March 20, 2014Applicant: GTx, Inc.Inventors: James T. Dalton, Mitchell S. Steiner, Ramesh Narayanan, Sunjoo Ahn
-
Publication number: 20140073662Abstract: The invention relates to substituted carbo- and heterocyclic spiro compounds of the formula Ia which inhibit thiol proteases, to processes for their preparation and to the use thereof as medicaments.Type: ApplicationFiled: November 22, 2013Publication date: March 13, 2014Applicant: SanofiInventors: Manfred SCHUDOK, Michael WAGNER, Armin BAUER, Anna KOHLMANN
-
Publication number: 20140073611Abstract: The disclosure relates to a platform of using zebrafish in screening candidates for treating and/or preventing myopia and keratoconus disease. The disclosure is mainly based on that Lumican, one of several SLRPs, plays an important role in the regulation of fibrillogenesis or the genes affecting the size of eyeballs in zebrafish, in addition to playing an important role in clinical myopia. Therefore, the disclosure uses the established zebrafish model to further identify the drugs affecting the expression of lumican and collagen fibrillogenesis, and/or the regulation of eyeball size. These drugs are potential candidates for treating myopia and/or keratoconus disease.Type: ApplicationFiled: May 21, 2013Publication date: March 13, 2014Applicant: National Taiwan UniversityInventors: I-Jong Wang, Wei-Ting Ho, Ting-Hsuan Chiang, I-Tsen Lin
-
Patent number: 8669286Abstract: This invention is directed to a feed composition and method of affecting the carcass composition by increasing the lean mass, reducing the fat mass, and/or reducing the percent fat mass comprising SARM compounds.Type: GrantFiled: September 26, 2012Date of Patent: March 11, 2014Assignee: University of Tennessee Research FoundationInventors: James T. Dalton, Duane D. Miller, Jeffrey D. Kearbey
-
Publication number: 20140066399Abstract: The present invention relates to topical preparations containing N-palmitoyl-vanillamide having hyperalgesic activity. In particular, the invention relates to N-palmitoyl-vanillamide for use in the treatment of pathologies selected from: post-herpetic neuralgia, neuralgia of trigeminus, occipital neuralgia, dental neuralgia, glottopharyngeal neuralgia, uremic neuralgia, diabetic neuralgia, headache of different origin, neuropathic itch, neurogenic itch, uremic itch, vulvodinia, vulvar vestibulitis, ano-rectal pain and itch, balano-preputial pain and itch, painful urogenital disorders of dogs and cats, psoriasis-associated pruritus and pain, itching skin diseases (e.g. atopic dermatitis) in the human and veterinary field, muscular pain, pain of the tendon, osteoarthritis associated pain in humans, dogs and cats; painful eye diseases in the human and veterinary field, inflammatory pathologies of the oral cavity in the human and veterinary field.Type: ApplicationFiled: August 28, 2013Publication date: March 6, 2014Applicant: EPITECH GROUP S.R.L.Inventors: Francesco Della Valle, Luciano De Petrocellis, Sabatino Maione, Vincenzo Di Marzo, Maria Federica Della Valle
-
Publication number: 20140066515Abstract: The present invention is directed to the use of a class of peptide compounds for treating diseases associated with hyperexcitability. The present invention is also directed to the use of a class of peptide compounds for treating diseases associated with dysfunction of an ion channel.Type: ApplicationFiled: September 10, 2013Publication date: March 6, 2014Applicant: UCB Pharma GmbHInventors: Cara Heers, Thomas Stoehr, Bettina Beyreuther
-
Patent number: 8664440Abstract: A method for preparing Aliskiren and intermediate thereof, which comprises the following steps: reacting 4-bromo-1-methoxy-2-(3-methoxypropoxy)benzene with magnesium isopropyl chloride and n-BuLi to obtain the compound of formula XXII; reacting the product of methylsulfonylation of the compound of formula XIX with anhydrous LiBr to obtain the compound of formula XXI; obtaining the intermediate of Aliskiren shown as formula XV by reacting the compound of formula XXII with the compound of formula XXI in an ether as the solvent and in the presence of a catalyst containing iron; then reacting the compound of formula XV with the compound of formula VII to obtain the compound of formula XXIII, following removing R1 from the amino group and obtaining Aliskiren shown as formula I.Type: GrantFiled: April 19, 2010Date of Patent: March 4, 2014Assignee: Zhejiang Tianyu Pharmaceutical Co., LtdInventors: Yongjun Tu, Yi Zhang, Rongde Cheng, Lingchao Peng
-
Publication number: 20140057984Abstract: Methods for preconditioning and/or providing neuroprotection to the animal central nervous system against the effects of ischemia, trauma, metal poisoning and neurodegeneration, including the associated cognitive, behavioral and physical impairments. Patients diagnosed with, or at risk for, certain diseases or disorders that are associated with risk for cerebral ischemia may benefit, e.g., those at risk for Alzheimer's disease, Parkinson's disease, corticobasal degeneration, Wilson's disease or stroke or those patients having head or spinal cord injury. Intranasal therapeutic agents are administered to the upper third of the nasal cavity to bypass the blood-brain barrier and access the central nervous system directly to avoid unwanted and potentially lethal side effects. Therapeutic agents include those substances that interact with iron and/or copper such as iron chelators, copper chelators, and antioxidants. A particular example of such therapeutic agents is the iron chelator deferoxamine (DFO).Type: ApplicationFiled: November 1, 2013Publication date: February 27, 2014Applicant: HealthPartners Research FoundationInventors: William H. Frey II, Sameul Scott Panter, Leah Ranae Bresin Hanson
-
Publication number: 20140051763Abstract: The present invention comprises methods and pharmaceutical compositions for intranasal delivery of effective amounts of DFO directly to the CNS, in particular the brain treatments that inhibit GSK3b in patients with psychiatric disorders including, but not limited to, bipolar disorder, depression, ADHD and schizophrenia. In addition a treatment composition is disclosed which comprises DFO and in certain embodiments combines DFO with one or more of the psychotropic drug types, i.e., antipsychotics, mood stabilizers and antidepressants. Moreover, a treatment for treating impairment of neural plasticity through inhibition of GSK3b is provided as well as prevention of apoptosis of cells through inhibition of GSK3b.Type: ApplicationFiled: October 28, 2013Publication date: February 20, 2014Applicant: HealthPartners Research FoundationInventors: Leah Ranae Bresin Hanson, William H. Frey, II
-
Publication number: 20140051685Abstract: The present invention is directed to a method for treating a patient suffering from a metabolic disorder such as the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes, and the metabolic sequale of these diseases including cardiovascular, cerebrovascular, renal and hepatic diseases, comprising the step of: administering to a patient suffering from the metabolic syndrome, Type 2 diabetes, obesity, or prediabetes a pharmaceutical composition comprising (1) at least one compound that stimulates an increase in central dopaminergic neuronal activity level in the subject, and (2) at least one compound that stimulates a decrease in central noradrenergic neuronal activity level in the subject.Type: ApplicationFiled: November 21, 2011Publication date: February 20, 2014Inventor: Anthony H. Cincotta
-
Publication number: 20140051678Abstract: The present invention relates to compounds which are inhibitors of the activity of Complex III of the mitochondrial electron transport chain and pharmaceutical compositions comprising said compounds alone or in combination with other active agents. The present invention further relates to use of the compounds of the invention as medicaments or as agrochemicals where their properties as inhibitors of the mitochondrial respiration is of benefit. More particularly the present invention relates to the use of the compounds of the invention in a method of treating and/or preventing cancers presenting tumor-initiating cells.Type: ApplicationFiled: November 24, 2011Publication date: February 20, 2014Applicant: STEMERGIE BIOTECHNOLOGY SAInventors: Virginie Clement-Schatlo, Thomas Fessard, Riccardo Cribiu
-
Publication number: 20140050775Abstract: Disclosed are compounds, compositions and methods for systemic and local delivery of biologically active molecules.Type: ApplicationFiled: March 8, 2013Publication date: February 20, 2014Applicant: Egen, Inc.Inventors: Gregory Slobodkin, Richard Congo, Majed Matar, Jason Fewell, Khursheed Anwer, Brian Jeffery Sparks
-
Publication number: 20140051762Abstract: Aspects of the present invention relate to compounds and methods useful in modulating angiogenesis and methods of treating or preventing diseases associated with angiogenesis by administering a polycationic compound. The present invention relates to methods of use and compositions for inhibiting angiogenesis-mediated disorders in mammals including animals and humans. Additionally, this invention relates to the combined use of polycations with other anti-angiogenesis agents for the treatment of different angiogenesis-mediated disorders. Additionally, those polycationic compounds can be used with various anti-inflammatory and cytotoxic agents as well as with radio-therapeutic agents in cancer patients to prevent and treat tumor growth and metastasis.Type: ApplicationFiled: August 12, 2013Publication date: February 20, 2014Inventors: Shaker Mousa, Dahui Liu
-
Publication number: 20140051716Abstract: There is provided a compound which is a histone deacetylase (HDAC) inhibitor, or a pharmaceutically acceptable ester, amide, solvate or salt thereof, for use in: (I) treating or preventing a pathological condition associated with excess fibrin deposition and/or thrombus formation; and/or (II) potentiating the degradation of fibrin deposits and preventing such deposits associated with pathological conditions or which may lead to such conditions, wherein the HDAC inhibitor, and the dose thereof, is as described in the description. There is also provided valproic acid, or a pharmaceutically acceptable salt thereof, for use in improving or normalizing endogenous fibrinolysis impaired by local or systemic inflammation.Type: ApplicationFiled: March 9, 2012Publication date: February 20, 2014Applicant: Cereno Scientific ABInventors: Pia Larsson, Niklas Bergh, Sverker Jern
-
Publication number: 20140039059Abstract: The use of substances capable of inhibiting one or more enzymes of the histone deacetylase family (histone deacetylase inhibitors) for the therapeutic treatment of Philadelphia-negative myeloproliferative syndromes (polycythemia vera, essential thrombocythemia or idiopathic myelofibrosis) is described. The dosage of the above-mentioned substances is significantly lower than that normally used for the care of other tumour syndromes and may be from 10 to 150 mg/day/patient.Type: ApplicationFiled: October 7, 2013Publication date: February 6, 2014Applicant: ITALFARMACO SPAInventors: Tiziano Oldoni, Paolo Mascagni, Alessandro Rambaldi, Tiziano Barbui
-
Patent number: 8642656Abstract: A class of topomimetic calixarene-based peptide mimetics is described. Calixarene-based peptide mimetics have various biological activities such as, for example, bactericidal activity, antiangiogenic activity, and/or antitumor activity. Methods of use and methods of designing calixarene-based peptide mimetics are described.Type: GrantFiled: September 28, 2012Date of Patent: February 4, 2014Assignee: Regents of the University of MinnesotaInventors: Kevin H. Mayo, Thomas R. Hoye, Xuemei Chen
-
Publication number: 20140031370Abstract: A compound represented by Formula (1): The compound can be used as insecticides.Type: ApplicationFiled: September 20, 2013Publication date: January 30, 2014Applicant: MITSUI CHEMICALS, INC.Inventors: Kei Yoshida, Takeo Wakita, Hiroyuki Katsuta, Akiyoshi Kai, Yutaka Chiba, Kiyoshi Takahashi, Hiroko Kato, Nobuyuki Kawahara, Michikazu Nomura, Hidenori Daido, Junji Maki, Shinichi Banba
-
Publication number: 20140011882Abstract: Disclosed are 5-nitrobenzoate derivatives of Formula I, and the preparation method therefor, wherein R is referred to hydrogen (H), unsubstituted, mono-substituted, di-substituted or tri-substituted benzoyl moiety. 5-Nitrobenzoate derivatives of Formula I do not affect the platelet aggregation, possesses the inhibitory activity related to the tumor cell-induced platelet aggregation (TCIPA), and further specifically inhibits podoplanin-induced platelet aggregation. Therefore, 5-nitrobenzoates of the invention are applicable in its therapeutic use as the novel therapeutic agent in preventing tumor metastasis.Type: ApplicationFiled: November 28, 2012Publication date: January 9, 2014Applicant: CHANG GUNG UNIVERSITYInventors: CHING-PING TSENG, PEI-WEN HSIEH, YAO-WEN CHANG
-
Patent number: 8623338Abstract: The invention concerns a methionine-derived peptidomimetic represented by the following general formula (II): R?X—C(O)—NH— with X=alkyl or alkyloxy (C1-C4); R??H The invention also concerns a composition for preventing or fighting cutaneous disorders associated to a mitochondrial dysfunction, and the use of a methionine-derived peptidomimetic as a cosmetic agent for protecting and/or stimulating the mitochondria of cutaneous cells.Type: GrantFiled: September 16, 2011Date of Patent: January 7, 2014Assignee: Exsymol S.A.M.Inventor: Marie-Christine Seguin
-
Publication number: 20140005048Abstract: Disclosed is a solid arthropodicide composition comprising by weight (a) from 0.3 to 100% of a particulate component comprising particles of a solid carrier infiltrated with a mixture comprising (i) one or more carboxamide arthropodicides and (ii) a surfactant constituent; (b) from 0 to 50% of a surfactant component having dispersing and wetting properties; and (c) from 0 to 99.7% of one or more additional formulating ingredients. Also disclosed is a propagule contacted with a biologically effective amount of said composition.Type: ApplicationFiled: September 5, 2013Publication date: January 2, 2014Applicant: E I Du Pont De Nemours And CompanyInventors: OLIVER WALTER GUTSCHE, John Henry Green
-
Publication number: 20140005263Abstract: This invention provides methods for treatment and inhibition of a male subject having an Androgen Decline in Aging Male (ADAM)-associated condition, for example sexual dysfunction, decreased sexual libido, erectile dysfunction, hypogonadism, sarcopenia, osteopenia, osteoporosis, an alteration in cognition and mood, depression, anemia, hair loss, obesity, muscle loss, dry eye, memory loss, benign prostate hyperplasia and/or prostate cancer, by administering to the subject a selective androgen receptor modulator (SARM) compound and/or its analog, derivative, isomer, metabolite, pharmaceutically acceptable salt, pharmaceutical product, hydrate, N-oxide, pro-drug, polymorph, crystal, or any combination thereof.Type: ApplicationFiled: May 21, 2013Publication date: January 2, 2014Applicant: University of Tennessee Research FoundationInventors: James T. Dalton, Duane D. Miller, Donghua Yin, Yali He
-
Patent number: 8618174Abstract: The invention relates to a combination comprising the renin inhibitor of formula (I) or a pharmaceutically acceptable salt thereof.Type: GrantFiled: September 19, 2011Date of Patent: December 31, 2013Assignee: Novartis AGInventors: William Hewitt, Daniel L Vasella, Randy L Webb
-
Patent number: 8618171Abstract: Encapsulated oil-in-water type emulsion compositions, which comprise an acylamino acid alkylamide or an acylglutamine alkyl ester, an oily base, a polar solvent and water, do no exhibit coalescence of the dispersed phase, and can be produced by a simple method without resort to a special apparatus, are excellent in stability with time, do not impart an uncomfortable feeling during application, are excellent in a sensory feeling that satisfies both a moisturizing feeling and an emollient feeling, and are excellent in appearance.Type: GrantFiled: January 17, 2007Date of Patent: December 31, 2013Assignee: Ajinomoto Co., Inc.Inventors: Tatsuki Ueyama, Tatsuya Hattori
-
Patent number: 8618173Abstract: Novel aromatic compounds of formula (I): wherein A1, A2, A3, A4, R1, R2, R5, G1, G2, Q1, Q2, Y1, Y2, Y3 and Y4 are as defined in claim 1; or a salt or N-oxide thereof. Furthermore, the present invention relates to processes for preparing compounds of formula (I), to insecticidal, acaricidal, nematicidal or molluscicidal compositions comprising them and to methods of using them to combat and control insect, acarine, nematode or mollusc pests.Type: GrantFiled: October 13, 2008Date of Patent: December 31, 2013Assignee: Syngenta Crop Protection, LLCInventors: Andre Denis Stoller, Pierre Joseph Marcel Jung, Christopher Richard Ayles Godfrey, William Lutz, Peter Maienfisch, Werner Zambach
-
Patent number: 8617595Abstract: The present invention relates to a solid oral dosage form comprising a therapeutically effective amount of aliskiren or a pharmaceutically acceptable salt thereof, and wherein the active ingredient is present in an amount of more than 46% by weight based on the total weight of the oral dosage form.Type: GrantFiled: March 16, 2005Date of Patent: December 31, 2013Assignee: Novartis AGInventors: Petra G Rigassi-Dietrich, Martin Schmid